dmLT佐剂经皮内免疫铜绿假单胞菌疫苗可防急性肺炎
本研究在小鼠模型中评估经皮内接种铜绿假单胞菌外膜蛋白(OMPs)联合大肠杆菌热不稳定毒素双突变体佐剂(dmLT)的保护效果。结果显示,与对照组相比,免疫小鼠肺部抗原特异性IgG及Th1、Th17型CD4+记忆T细胞显著增多,并显著抵抗致死性肺部感染,保护与肺部早期IFN-γ和IL-17产生相关。
要点
- OMPs+dmLT经皮内免疫可诱导肺部抗原特异性IgG和Th1/Th17记忆CD4+T细胞。
- 该免疫策略显著保护小鼠抵抗致死性铜绿假单胞菌肺部感染。
- 保护效应与肺部早期IFN-γ和IL-17产生相关。
核心结论
- 经皮内接种dmLT佐剂可驱动肺部黏膜保护性免疫,可能是针对多种呼吸道病原体的可行疫苗策略。
研究设计与样本
- 小鼠模型研究,比较OMPs+dmLT经皮内免疫组与对照组。
主要发现
- 免疫小鼠肺部抗原特异性IgG及Th1、Th17型CD4+记忆T细胞显著多于对照组。
- 免疫小鼠显著抵抗致死性肺部感染。
- 保护与肺部早期IFN-γ和IL-17产生相关。
临床怎么用
- 提示经皮内接种dmLT佐剂疫苗可能用于诱导肺部黏膜免疫以预防呼吸道感染。
局限性
- 证据来自小鼠模型,尚未在人体验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Respiratory infections are a leading cause of morbidity and mortality globally. This is partially due to a lack of effective vaccines and a clear understanding of how vaccination route and formulation influence protective immunity in mucosal tissues such as the lung. Pseudomonas aeruginosa is an opportunistic pathogen capable of causing acute pulmonary infections and is a leading cause of hospital-acquired and ventilator-associated pneumonia. With multidrug-resistant P. aeruginosa infections on the rise, the need for a vaccine against this pathogen is critical. Growing evidence suggests that a successful P. aeruginosa vaccine may require mucosal antibody and Th1- and Th17-type CD4+ T cells to prevent pulmonary infection. Intradermal immunization with adjuvants, such as the bacterial ADP-Ribosylating Enterotoxin Adjuvant (BARE) double mutant of E. coli heat-labile toxin (dmLT), can direct protective immune responses to mucosal tissues, including the lungs. We reasoned that intradermal immunization with P. aeruginosa outer membrane proteins (OMPs) adjuvanted with dmLT could drive neutralizing antibodies and migration of CD4+ T cells to the lungs and protect against P. aeruginosa pneumonia in a murine model. Here we show that mice immunized with OMPs and dmLT had significantly more antigen-specific IgG and Th1- and Th17-type CD4+ memory T cells in the pulmonary environment compared to control groups of mice. Furthermore, OMPs and dmLT immunized mice were significantly protected against an otherwise lethal lung infection. Protection was associated with early IFN-γ and IL-17 production in the lungs of immunized mice. These results indicate that intradermal immunization with dmLT can drive protective immunity to the lung mucosa and may be a viable vaccination strategy for a multitude of respiratory pathogens.
引用
- Baker SM, Pociask D, Clements JD, et al. Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted with a mutant bacterial ADP-ribosylating enterotoxin protects against acute pneumonia. Vaccine. 2019. PMID: 30638799. doi:10.1016/j.vaccine.2018.12.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。